Cachet Pharmaceuticals Private Limited

Cachet Pharmaceuticals Private Limited, established in 1978, is a prominent Indian pharmaceutical company specializing in the manufacturing and marketing of a diverse range of pharmaceutical formulations and nutraceuticals. The company is headquartered in Patna, Bihar, India, with its registered office located at Exhibition Road, P.S.-Gandhi Maidan, Patna, Bihar 800001. Cachet operates as a private limited company, classified under the Corporate Identification Number (CIN) U24230BR1978PTC001328. The authorized capital stands at ₹40,00,000, with a paid-up capital of ₹17,83,400. The company employs a workforce of over 1,400 individuals, reflecting its significant presence in the pharmaceutical sector. Cachet's product portfolio encompasses various therapeutic segments, including antibiotics, NSAIDs, gastrointestinal agents, nutritional supplements, anti-osteoporosis medications, and gynecological products. Leading brands include Traxol, Traxol-S, Traxol-T, Lysoflam, NE, I-UP, Cavit-PM, PNZ, PNZ-D, Vitoc-D, Cadbe, Vitzin, Pamagin, P40, Moxate, Capritaz, Merotiva, and Cachpar.

Cachet Pharmaceuticals operates two primary manufacturing facilities in India. The first is located in Bhiwadi, Rajasthan, covering an area of 65,000 square feet. This plant is equipped with state-of-the-art manufacturing facilities and has been certified by WHO-GMP and ISO 9001:2000. The second facility is situated in Baddi, Himachal Pradesh, and is designed to accommodate increased production capacity. Both plants are authorized by the FDA and WHO, ensuring compliance with international quality standards.

The leadership team at Cachet Pharmaceuticals comprises several key individuals:

• Satish Kumar Singh: Managing Director, appointed on 16 June 2001.

• Anuja Madhurendra Sinha: Director, appointed on 16 November 2015.

• Arunkumar Dattatray Deshmukh: Director, appointed on 15 June 2015.

• Premlata Singh: Director, appointed on 30 May 2019.

These leaders are responsible for steering the company's strategic direction and ensuring its growth and compliance with industry standards.

Cachet Pharmaceuticals has established a presence in several regulated markets, including the United States, European Union, United Kingdom, and Australia. The company's manufacturing facilities in Bhiwadi and Baddi have been inspected and approved by the FDA and WHO, indicating compliance with international quality standards. While specific regulatory filings and approvals in these markets are not detailed in the available sources, the company's adherence to WHO-GMP and ISO 9001:2000 certifications suggests a commitment to meeting the stringent requirements of these regions.

Cachet Pharmaceuticals has expanded its reach to over 30 countries, with more than 500 product registrations. This global footprint includes markets in Africa, Latin America, and Southeast Asia. The company's adherence to WHO-GMP standards facilitates access to these emerging markets, ensuring product quality and safety.

Cachet Pharmaceuticals demonstrates a diversified geographic strategy by operating in over 30 countries, including emerging markets in Africa, Latin America, and Southeast Asia. This broad international presence mitigates concentration risk and positions the company to leverage growth opportunities across different regions. The company's adherence to WHO-GMP standards further supports its strategic direction, ensuring product quality and facilitating market access.

Cachet Pharmaceuticals' manufacturing facilities in Bhiwadi and Baddi have been inspected and approved by the FDA, indicating compliance with international quality standards. While specific details regarding FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not provided in the available sources, the company's adherence to WHO-GMP and ISO 9001:2000 certifications suggests a commitment to meeting the stringent requirements of the FDA.

Cachet Pharmaceuticals' manufacturing facilities are certified by WHO-GMP and ISO 9001:2000, reflecting compliance with international quality standards. While specific EU GMP certificates and EDQM status are not detailed in the available sources, the company's adherence to WHO-GMP standards suggests a commitment to meeting the stringent requirements of the European Union.

Cachet Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's manufacturing facilities in Bhiwadi and Baddi are authorized by the FDA and WHO, indicating adherence to international quality standards. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not provided in the available sources.

As of March 2026, there are no publicly available records of FDA Form 483 observations, warning letters, or import alerts associated with Cachet Pharmaceuticals. The company's adherence to WHO-GMP and ISO 9001:2000 certifications suggests a proactive approach to maintaining compliance with regulatory standards.

Cachet Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. While specific competitors in overlapping categories are not detailed in the available sources, the company's diversified product portfolio and international presence position it to effectively compete in various therapeutic segments. The company's adherence to WHO-GMP and ISO 9001:2000 certifications further enhances its competitive standing by ensuring product quality and regulatory compliance.

Cachet Pharmaceuticals' key differentiators include its diversified product portfolio covering multiple therapeutic segments, including pain management, gynecology, and anti-infectives. The company's manufacturing facilities are certified by WHO-GMP and ISO 9001:2000, reflecting compliance with international quality standards. Additionally, Cachet's global presence in over 30 countries and more than 500 product registrations demonstrate its ability to meet diverse market needs.

Cachet Pharmaceuticals is strategically positioned as a manufacturer and marketer of a wide range of pharmaceutical formulations and nutraceuticals. The company's diversified product portfolio spans acute and chronic therapies, including pain management, gynecology, and anti-infectives. With a global presence in over 30 countries and more than 500 product registrations, Cachet is well-positioned to leverage growth opportunities across diverse markets.

Cachet Pharmaceuticals has demonstrated a consistent track record in the pharmaceutical industry, with over four decades of experience. The company has consistently registered a turnover of over ₹400 crores in the preceding three financial years and is striving to achieve ₹1,000 crores in the coming years. The company's adherence to WHO-GMP and ISO 9001:2000 certifications reflects its commitment to maintaining high-quality manufacturing standards. Cachet's global presence in over 30 countries and more than 500 product registrations further underscores its reliability as a supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• WHO-GMP Certification: Indicates compliance with World Health Organization Good Manufacturing Practices.

• ISO 9001:2000 Certification: Demonstrates adherence to international quality management standards.

These certifications can typically be verified through the company's official website or by contacting the company directly.

When considering Cachet Pharmaceuticals as a supplier, importers should undertake the following verification steps:

• Review Certifications: Confirm